COVID-19
2022
EUA for Novavax COVID-19 Vaccine Booster in Select Patients (Oct 2022) [PDF - 273 KB]
FDA Authorizes Bivalent COVID-19 Boosters in Younger Age Groups (Oct 2022) [PDF - 263 KB]
FDA Approves Bivalent COVID-19 Vaccines as Booster (Sept 2022) [PDF - 272 KB]
Novavax COVID-19 vaccine EUA expansion to include ages 12 through 17 years (Aug 2022) [PDF - 378 KB]
FDA issues EUA for Novavax COVID-19 vaccine (July 2022) [PDF - 266 KB]
FDA authorizes revisions to Evusheld dosing (July 2022) [PDF - 57 KB]
FDA Authorizes Pharmacists To Prescribe Paxlovid (July 2022) [PDF - 189 KB]
CDC recommends Moderna Vaccine in Children Ages 6 Years through 17 Years (June 2022) [PDF - 197 KB]
FDA Authorizes Moderna and Pfizer COVID-19 Vaccines Down to Children Aged 6 Months (June 2022) [PDF - 236 KB]
Paxlovid & COVID-19 Rebound (May 2022) [PDF - 116 KB]
FDA Exapnds Pfizer BioNTech Vaccine Booster Dose to Children 5 through 11 Years (May 2022) [PDF - 137 KB]
FDA limits Use of Janssen COVID-19 Vaccine (May 2022) [PDF - 407 KB]
FDA expands approval of Remdesevir (VEKLURY) for pediatric patients down to 28 days of age (April 2022) [PDF - 387 KB]
Drug Safety Alert: Paxlovid Renal Dose Packs Availability (Apr 2022) [PDF - 121 KB]
Distribution of Sotrovimab Paused to all US States and Territories (Apr 2022) [PDF - 279 KB]
FDA Authorizes Second Booster Dose for Older and Immunocompromised Individuals (Mar 2022) [PDF - 203 KB]
Distribution of Sotrovimab Paused to Certain States (Mar 2022) [PDF - 385 KB]
NPTC Meeting COVID-19 Update (Feb 2022) [PDF - 222 KB]
Eight week mRNA Vaccine intervals (Feb 2022) [PDF - 117 KB]
Revised Interim Clinical Considerations (Feb 2022) [PDF - 121 KB]
EUA for monoclonal antibody, bebtelovimab (Feb 2022) [PDF - 277 KB]
FDA approves (Spikevax) Moderna COVID-19 vaccine (Feb 2022) [PDF - 342 KB]
FDA Limits Use of Bamlanivimab/Etesevimab and REGEN-COV (Jan 2022) [PDF - 461 KB]
FDA Expands Use of Remdesivir for Outpatients With Mild-to-Moderate COVID-19 (Jan 2022) [PDF - 621 KB]
Moderna COVID-19 Booster Interval Shortened To Five Months (Jan 2022) [PDF - 98 KB]
FDA expands use of Pfizer-BioNtech COVID-19 vaccine EUA (Jan 2022) [PDF - 287 KB]
2021
HHS Pause in Distribution of MABs & Omicron Variant (Dec 2021) [PDF - 295 KB]
EUA for oral antiviral molnupiravir (Dec 2021) [PDF - 277 KB]
EUA for oral nirmatrelvir-ritonavir [Paxlovid®] (Dec 2021) [PDF - 275 KB]
Drug Safety Alert_Janssen COVID-19 Vaccine EUA Update: Increased risk of TTS (Dec 2021) [PDF - 201 KB]
Pfizer-BioNTech COVID-19 Vaccine (expanded EUA) Booster Dose in 16 and 17 Year Olds (Dec 2021) [PDF - 327 KB]
Tixagevimab and Cilgavimab (Evusheld) EUA (Dec 2021) [PDF - 286 KB]
Bamlanivimab-Etesevimab EUA expanded for COVID Treatment and Post-Exposure Prophylaxis in Pediatrics and Newborns (Dec 2021) [PDF - 412 KB]
FDA Expands Eligibility for COVID-19 Vaccine Boosters (Nov 2021) [PDF - 298 KB]
Pfizer-BioNTech COVID-19 Vaccine expanded for children aged 5-11 years (Nov 2021) [PDF - 289 KB]
Moderna and Janssen Vaccine Boosters & Mix and Match (Oct 2021) [PDF - 656 KB]
Pfizer-BioNTech Vaccine Booster (Sept 2021) [PDF - 689 KB]
EUA Update: Resumption of Bamlanivumab-Etesevimab Use (Sept 2021) [PDF - 197 KB]
Third Dose for Immune Compromised (August 2021) [PDF - 706 KB]
Updates to REGEN-COV EUA (August 2021) [PDF - 756 KB]
FDA Surveillance of 4 Adverse Events of Interest & Pfizer/BioNTech Vaccine (July 2021) [PDF - 126 KB]
Guillain-Barré Syndrome & Janssen/Johnson and Johnson COVID-19 Vaccine (July 2021) [PDF - 230 KB]
Tocilizumab EUA (July 2021) [PDF - 738 KB]
Casirivimab and Imdevimab (REGEN-COV) EUA Update (June 2021) [PDF - 728 KB]
Bamlanivumab-Etesevimab Distribution Paused (June 2021) [PDF - 294 KB]
FDA warning: mRNA COVID-19 vaccines & myo- and pericarditis (June 2021) [PDF - 146 KB]
Sotrovimab EUA (June 2021) [PDF - 757 KB]
05-2021 COVID Vaccine and myo_pericarditis (June 2021) [PDF - 106 KB]
Suspected COVID-19 P.1 Variant Resistance to bamlanivimab/etesevimab (May 2021) [PDF - 159 KB]
Amended EUA: Pfizer-BioNTech COVID-19 Vaccine_Use in Adolescents Aged 12-15 years (May 2021) [PDF - 244 KB]
COVID-19 Clinical Update - NPTC Meeting (April 2021) [PDF - 199 KB]
Drug Safety Alert_Johnson & Johnson/Janssen Vaccine Update (April 2021) [PDF - 105 KB]
Revocation of Bamlanivimab monotherapy EUA (April 2021) [PDF - 526 KB]
Johnson & Johnson/Janssen COVID-19 Vaccine (April 2021) [PDF - 143 KB]
Janssen COVID-19 Vaccine EUA (Mar 2021) [PDF - 543 KB]
Bamlanivimab and Etesevimab EUA (Feb 2021) [PDF - 748 KB]
NPTC COVID-19 Emerging Treatments & Vaccine Update (Jan 2021) [PDF - 188 KB]
COVID-19 Vaccine Safety Alert: Anaphylaxis (Jan 2021) [PDF - 356 KB]
2020
Moderna COVID-19 Vaccine EUA (Dec 2020) [PDF - 151 KB]
Pfizer-BioNTech-COVID-19-Vaccine EUA (Dec 2020) [PDF - 276 KB]
CDC "v-safe" Vaccination Health Checker [PDF - 137 KB]
Baricitinib + Remdesivir EUA (Nov 2020) [PDF - 295 KB]
Casirivimab and Imdevimab EUA (Nov 2020) [PDF - 789 KB]
Bamlanivimab EUA (Nov 2020) [PDF - 638 KB]
COVID-19 Vaccines Overview (Nov 2020) [PDF - 145 KB]
Routine Vaccination During COVID-19 (Nov 2020) [PDF - 196 KB]
FDA Approval: Remdesivir (Oct 2020) [PDF - 644 KB]
Reporting Adverse Vaccine Events handout (October 2020)
COVID-19 Convalescent Plasma (August 2020)
Remdesivir (Veklury) EUA Update (August 2020)
COVID-19 Impact and Therapies (July 2020)
Dexamethasone for COVID-19 (July 2020)
Revocation of Hydroxychloroquine EUA for COVID-19 (June 2020)
Remdesivir Transfer Guidance (June 2020)
Remdesivir Treatment Priorotization Strategy (June 2020)
Remdesivir (GS-5734) (May 2020)
FDA Drug Safety Communication: Hydroxychloroquine and Heart Rhythm ADEs (April 2020)
Hydroxychloroquine for COVID-19 (March 2020) [PDF - 172 KB]
Unknown Risks with Unapproved COVID-19 Treatments (March 2020)
Vaccinations and COVID-19 (March 2020) [PDF - 101 KB]
Nebulizers and COVID-19 (March 2020) [PDF - 346 KB]
CDC Health Safety Alert: Non-pharmaceutical Chloroquine (March 2020)
